Document is current
Any future updates will be listed below
-
Authors
Baker, Ethan A. G. https://orcid.org/0000-0003-1833-8053
Schapiro, Denis https://orcid.org/0000-0002-9391-5722
Dumitrascu, Bianca https://orcid.org/0000-0001-8328-2354
Vickovic, Sanja https://orcid.org/0000-0003-0985-9885
Regev, Aviv https://orcid.org/0000-0003-3293-3158
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (BMBF 01ZZ2004)
Damon Runyon Cancer Research Foundation (DRQ-03-20)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2ZHP3_181475)
National Science Foundation (1745302, DMS-1638352, DMS-1638521)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (HHSN261201500003I, HHSN261100039)
Royal Swedish Academy of Sciences
Svenska Läkaresällskapet
KMB Foundation
- License Information
-
More Information
Article History
Received: 13 January 2022
Accepted: 15 January 2023
First Online: 2 March 2023
Competing interests
: A. R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and until 31 August 2020 was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov, and ThermoFisher Scientific. From 1 August 2020, A. R. is an employee of Genentech, and has equity in Roche. From 6 June 2022, E. A. G. B. is an employee of Enable Medicine. D. S. reports funding from GSK. The remaining authors declare no competing interests.
